Skip to main content
    N

    Nuvation Bio Inc (NUVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $3.86
    -0.13 (-3.26%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nuvation Bio Inc (NUVB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Nuvation Bio reported revenue of $62.90M for the fiscal year ended Dec 31, 2025. That year, net income was -$204.63M with a net margin of -325.3%, operating cash flow was -$173.43M and free cash flow was -$181.78M. The quarter ended Sep 30, 2026 had revenue of $44.95M and net income of -$41.90M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$62.90MN/A100.0%-338.7%-325.3%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$62.90M$0$0$0$0$0N/AN/A
    Gross profit$62.90M$0$0$0$0$0N/AN/A
    Research and development$115.11M$524.19M$71.29M$87.81M$69.04M$32.60M$25.11M$482.67K
    Operating income-$213.06M-$592.63M-$99.82M-$119.73M-$93.32M-$43.55M-$32.10M-$992.00K
    Net income-$204.63M-$567.94M-$75.80M-$104.20M-$86.85M-$41.66M-$33.55M-$992.00K
    EBITDAN/AN/AN/A-$106.55M-$84.95MN/A-$32.09MN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$44.95M$31.69M$83.23M$41.87M$13.12M$4.83M$3.08M-$2.16M$727.00K$1.44M$0$264.00K
    Gross profit$44.95M$31.69M$83.23M$49.88M$13.12M$4.83M$3.08M$700.00K-$788.00K$88.00K$0$209.00K
    Operating income-$42.21M-$51.04M$3.88M-$34.04M-$56.43M-$63.59M-$59.00M-$53.94M-$48.10M-$470.38M-$20.20M-$20.83M
    Net income-$41.90M-$62.84M$5.40M-$36.59M-$55.79M-$59.01M-$53.24M-$49.45M-$41.21M-$462.49M-$14.79M-$13.79M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $52.93M by $111.15M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$594.82M$540.63M$621.48M$672.14M$776.15M$221.79M$120.95M$158.00K
    Current assets$571.52M$526.25M$616.43M$667.32M$772.07M$220.68M$119.89M$158.00K
    Cash and equivalents$164.09M$35.72M$42.65M$101.10M$132.42M$29.75M$3.47M$138.00K
    Total liabilities$289.11M$76.84M$16.36M$17.07M$30.15M$6.71M$3.20M$902.00K
    Short-term debt$5.72M$6.28M$0$1.21M$863.00KN/AN/A$600.00K
    Long-term debt$47.21M$0N/AN/AN/AN/AN/AN/A
    Shareholder equity$305.72M$463.79M$605.12M$655.08M$746.00M$215.08M$117.75M-$744.00K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$778.39M$744.50M$610.24M$594.82M$601.56M$647.23M$492.49M$540.63M$571.58M$594.80M$613.13M$621.48M
    Total liabilities$550.42M$490.64M$290.68M$289.11M$275.68M$274.32M$73.03M$76.84M$68.86M$62.66M$19.08M$16.36M
    Cash and equivalents$153.77M$258.60M$125.39M$164.09M$98.90M$247.97M$47.98M$35.72M$30.04M$34.28M$34.51M$42.65M
    Shareholder equity$227.97M$253.86M$319.56M$305.72M$325.88M$372.91M$419.46M$463.79M$502.71M$257.19M$594.04M$605.12M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$173.43M-$130.41M-$68.00M-$96.11M-$68.19M-$36.53M-$24.43M-$616.00K
    Capital expenditures$8.35M$162.00K$69.00K$370.00K$282.00K$145.00K$659.00K$659.00K
    Free cash flow-$181.78M-$130.57M-$68.07M-$96.48M-$68.47M-$36.67M-$25.09M-$1.27M
    Investing cash flow$99.52M$122.70M$8.92M$63.46M-$454.67M-$70.32M-$115.86M-$115.86M
    Financing cash flow$202.53M$331.00K$628.00K$1.33M$625.53M$133.13M$143.62M$800.00K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$38.56M-$42.97M$5.07M-$29.73M-$52.89M-$48.18M-$42.63M-$46.30M-$31.09M-$37.32M-$15.70M-$15.03M
    Capital expenditures$1.59M$254.00K$48.00K$89.00K$8.01M$181.00K$72.00K$13.00K$148.00K$0$27.00K$13.00K
    Free cash flow-$40.15M-$43.22M$5.02M-$29.82M-$60.90M-$48.36M-$42.70M-$46.31M-$31.23M-$37.32M-$15.73M-$15.04M
    Last 12 quarters

    Frequently Asked Questions About NUVB

    What is Nuvation Bio's annual revenue?

    Nuvation Bio reported revenue of $62.90M for the fiscal year ended Dec 31, 2025.

    Is Nuvation Bio profitable?

    No. Nuvation Bio reported net income of -$204.63M for the fiscal year ended Dec 31, 2025, with a net margin of -325.3%.

    How much free cash flow does NUVB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$173.43M minus capital expenditures of $8.35M produced free cash flow of -$181.78M.

    How much debt does Nuvation Bio have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $47.21M, short-term debt of $5.72M and cash and equivalents of $164.09M.

    What is NUVB's profit margin?

    For the fiscal year ended Dec 31, 2025, Nuvation Bio reported gross margin of 100.0%, operating margin of -338.7% and net margin of -325.3%.